Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Advances in Diagnosis and Management of Retinal Diseases
share announcement

Advances in Diagnosis and Management of Retinal Diseases

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 573

Special Issue Editor

Dr. Antonio Ferreras

E-Mail Website
Guest Editor
Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain
Interests: retina; macula; glaucoma; imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Retinal disorders are a diverse and complex group of ophthalmic conditions that include retinal vascular diseases, macular diseases, retinal detachment, inherited retinal diseases, and choroidal tumors affecting the retina, all of which can seriously threaten vision and even lead to blindness. Therefore, early diagnosis and effective treatment are crucial.

This Special Issue will highlight the latest diagnostic technologies for retinal diseases, such as optical coherence tomography (OCT) and fundus fluorescein angiography, to aid clinicians in more accurately diagnosing such conditions.

Additionally, we will focus on basic research into the pathogenesis of retinal diseases, including changes in apoptosis, inflammatory response, angiogenesis, and more, which will aid in revealing the nature of the disease and provide a theoretical basis for effective treatment strategies.

Furthermore, we will explore the application of innovative technologies, such as artificial intelligence and big data, in the diagnosis of retinal diseases, providing more possibilities for accurate diagnosis.

We invite distinguished authors to submit original articles and reviews that explore the diagnosis, pathogenesis, treatment methods, and clinical practice of retinal diseases, providing a platform for ophthalmologists and researchers to gain a comprehensive understanding of and stay up-to-date with the latest advances in the field of retinal diseases.

Dr. Antonio Ferreras
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • retinal lesion
  • retinal imaging
  • optical coherence tomography
  • fluorescein angiography
  • funduscopic examination
  • biomarkers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1483 KiB  
Article
The Predictors of Early Treatment Effectiveness of Intravitreal Bevacizumab Application in Patients with Diabetic Macular Edema
by Karla Katić, Josip Katić, Marko Kumrić, Joško Božić, Leida Tandara, Daniela Šupe Domić and Kajo Bućan
Diagnostics 2024, 14(10), 992; https://doi.org/10.3390/diagnostics14100992 - 10 May 2024
Viewed by 429
Abstract
The aim of this study was to establish whether multiple blood parameters might predict an early treatment response to intravitreal bevacizumab injections in patients with diabetic macular edema (DME). Seventy-eight patients with non-proliferative diabetic retinopathy (NPDR) and DME were included. The treatment response [...] Read more.
The aim of this study was to establish whether multiple blood parameters might predict an early treatment response to intravitreal bevacizumab injections in patients with diabetic macular edema (DME). Seventy-eight patients with non-proliferative diabetic retinopathy (NPDR) and DME were included. The treatment response was evaluated with central macular thickness decrease and best corrected visual acuity increase one month after the last bevacizumab injection. Parameters of interest were the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), vitamin D, and apolipoprotein B to A-I ratio (ApoB/ApoA-I). The NLR (2.03 ± 0.70 vs. 2.80 ± 1.08; p < 0.001), MLR (0.23 ± 0.06 vs. 0.28 ± 0.10; p = 0.011), PLR (107.4 ± 37.3 vs. 135.8 ± 58.0; p = 0.013), and SII (445.3 ± 166.3 vs. 675.3 ± 334.0; p < 0.001) were significantly different between responder and non-responder groups. Receiver operator characteristics analysis showed the NLR (AUC 0.778; 95% CI 0.669–0.864), PLR (AUC 0.628; 95% CI 0.511–0.735), MLR (AUC 0.653; 95% CI 0.536–0.757), and SII (AUC 0.709; 95% CI 0.595–0.806) could be predictors of response to bevacizumab in patients with DME and NPDR. Patients with severe NPDR had a significantly higher ApoB/ApoA-I ratio (0.70 (0.57–0.87) vs. 0.61 (0.49–0.72), p = 0.049) and lower vitamin D (52.45 (43.10–70.60) ng/mL vs. 40.05 (25.95–55.30) ng/mL, p = 0.025). Alterations in the NLR, PLR, MLR, and SII seem to provide prognostic information regarding the response to bevacizumab in patients with DME, whilst vitamin D deficiency and the ApoB/ApoA-I ratio could contribute to better staging. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Management of Retinal Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop